These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38227143)

  • 1. Reliable detection of genetic alterations in cyst fluid DNA for the diagnosis of brain tumors.
    On J; Natsumeda M; Takahashi H; Koyama A; Shibuma S; Shibata N; Watanabe J; Saito S; Kanemaru Y; Tsukamoto Y; Okada M; Ogura R; Eda T; Tada M; Shimizu H; Adachi JI; Mishima K; Nishikawa R; Kakita A; Oishi M
    J Neurooncol; 2024 Jan; 166(2):273-282. PubMed ID: 38227143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
    Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A
    Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH1 mutation is detectable in plasma cell-free DNA and is associated with survival outcome in glioma patients.
    Crucitta S; Pasqualetti F; Gonnelli A; Ruglioni M; Luculli GI; Cantarella M; Ortenzi V; Scatena C; Paiar F; Naccarato AG; Danesi R; Del Re M
    BMC Cancer; 2024 Jan; 24(1):31. PubMed ID: 38172718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-free DNA as a diagnostic analyte for molecular diagnosis of vascular malformations.
    Zenner K; Jensen DM; Cook TT; Dmyterko V; Bly RA; Ganti S; Mirzaa GM; Dobyns WB; Perkins JA; Bennett JT
    Genet Med; 2021 Jan; 23(1):123-130. PubMed ID: 32884133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
    Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
    Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers.
    Yip S; Butterfield YS; Morozova O; Chittaranjan S; Blough MD; An J; Birol I; Chesnelong C; Chiu R; Chuah E; Corbett R; Docking R; Firme M; Hirst M; Jackman S; Karsan A; Li H; Louis DN; Maslova A; Moore R; Moradian A; Mungall KL; Perizzolo M; Qian J; Roldan G; Smith EE; Tamura-Wells J; Thiessen N; Varhol R; Weiss S; Wu W; Young S; Zhao Y; Mungall AJ; Jones SJ; Morin GB; Chan JA; Cairncross JG; Marra MA
    J Pathol; 2012 Jan; 226(1):7-16. PubMed ID: 22072542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
    van den Bent MJ; Dubbink HJ; Marie Y; Brandes AA; Taphoorn MJ; Wesseling P; Frenay M; Tijssen CC; Lacombe D; Idbaih A; van Marion R; Kros JM; Dinjens WN; Gorlia T; Sanson M
    Clin Cancer Res; 2010 Mar; 16(5):1597-604. PubMed ID: 20160062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
    Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
    Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Identification of genetic alterations by multiple ligation-dependent probe amplification (MLPA) analysis in oligodendrogliomas].
    Franco-Hernández C; Martínez-Glez V; Torres-Martín M; de Campos JM; Isla A; Vaquero J; Casartelli C; Rey JA
    Neurocirugia (Astur); 2009 Apr; 20(2):117-23. PubMed ID: 19448956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma.
    Andrews C; Prayson RA
    Ann Diagn Pathol; 2020 Jun; 46():151519. PubMed ID: 32305004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study.
    Habiba U; Sugino H; Yordanova R; Ise K; Tanei ZI; Ishida Y; Tanikawa S; Terasaka S; Sato KI; Kamoshima Y; Katoh M; Nagane M; Shibahara J; Tsuda M; Tanaka S
    Acta Neuropathol Commun; 2021 May; 9(1):95. PubMed ID: 34020723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.
    Xiong J; Liu Y; Wang Y; Ke RH; Mao Y; Ye ZR
    Chin Med J (Engl); 2010 Dec; 123(24):3566-73. PubMed ID: 22166632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic algorithm for pathological evaluation of gliomas in a resource-constrained setting.
    Jain S; Gupta P; Shankar KB; Singh R; Siraj F
    J Cancer Res Ther; 2023; 19(3):562-566. PubMed ID: 37470575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.
    Li S; Yan C; Huang L; Qiu X; Wang Z; Jiang T
    Neuro Oncol; 2012 Jan; 14(1):109-16. PubMed ID: 22039037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and epigenetic stability of oligodendrogliomas at recurrence.
    Aihara K; Mukasa A; Nagae G; Nomura M; Yamamoto S; Ueda H; Tatsuno K; Shibahara J; Takahashi M; Momose T; Tanaka S; Takayanagi S; Yanagisawa S; Nejo T; Takahashi S; Omata M; Otani R; Saito K; Narita Y; Nagane M; Nishikawa R; Ueki K; Aburatani H; Saito N
    Acta Neuropathol Commun; 2017 Mar; 5(1):18. PubMed ID: 28270234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification.
    Ammendola S; Broggi G; Barresi V
    Histol Histopathol; 2023 Jul; 38(7):739-753. PubMed ID: 36651583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression.
    Hoang-Xuan K; He J; Huguet S; Mokhtari K; Marie Y; Kujas M; Leuraud P; Capelle L; Delattre JY; Poirier J; Broët P; Sanson M
    Neurology; 2001 Oct; 57(7):1278-81. PubMed ID: 11591848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allelic status of 1p and 19q in oligodendrogliomas and glioblastomas: multiplex ligation-dependent probe amplification versus loss of heterozygosity.
    Franco-Hernández C; Martínez-Glez V; de Campos JM; Isla A; Vaquero J; Gutiérrez M; Casartelli C; Rey JA
    Cancer Genet Cytogenet; 2009 Apr; 190(2):93-6. PubMed ID: 19380026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.